Matthew Moyle, PhD
Time: Tuesday 29th August, 2:00pm
Venue: Cairns - B1.107 video linked to Townsville - 142-233
Discovery of therapeutic antibodies from human B cells
Human subjects who have been exposed to viral pathogens can offer a rich source of protective antibodies that have potential as novel therapeutic agents. We developed a platform that enabled the efficient selection of pathogen-specific antibodies with protective function directly from human blood samples, and used it to identify potent, broadly neutralizing and/or protective antibodies to HIV and influenza. The technology was further employed to identify tumor-specific antibodies from subjects recently diagnosed with cancer.
Biography: Matthew Moyle is a biopharma veteran with extensive experience in the discovery and development of novel therapeutic agents. He has led R&D groups at Boehringer Ingelheim, Amgen and Tanox, among others, resulting in the delivery of more than 20 drug candidates that have advanced to clinical testing. Several of these are currently in late stage development, including lampalizumab for dry AMD, lebrikizumab for fibrotic diseases (both at Roche), and ligelizumab for chronic urticaria (Novartis). Dr Moyle received his BSc and PhD degrees in Biochemistry from the University of Toronto, and completed postdoctoral studies at Genentech.